FULC
Price
$7.81
Change
-$0.01 (-0.13%)
Updated
Jul 25 closing price
Capitalization
421.58M
11 days until earnings call
MRNA
Price
$34.15
Change
+$0.14 (+0.41%)
Updated
Jul 25 closing price
Capitalization
13.21B
6 days until earnings call
Interact to see
Advertisement

FULC vs MRNA

Header iconFULC vs MRNA Comparison
Open Charts FULC vs MRNABanner chart's image
Fulcrum Therapeutics
Price$7.81
Change-$0.01 (-0.13%)
Volume$464.42K
Capitalization421.58M
Moderna
Price$34.15
Change+$0.14 (+0.41%)
Volume$5.37M
Capitalization13.21B
FULC vs MRNA Comparison Chart in %
Loading...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FULC vs. MRNA commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a Hold and MRNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (FULC: $7.81 vs. MRNA: $34.15)
Brand notoriety: FULC: Not notable vs. MRNA: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 88% vs. MRNA: 53%
Market capitalization -- FULC: $421.58M vs. MRNA: $13.21B
FULC [@Biotechnology] is valued at $421.58M. MRNA’s [@Biotechnology] market capitalization is $13.21B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileMRNA’s FA Score has 1 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • MRNA’s FA Score: 1 green, 4 red.
According to our system of comparison, FULC is a better buy in the long-term than MRNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 3 TA indicator(s) are bullish while MRNA’s TA Score has 6 bullish TA indicator(s).

  • FULC’s TA Score: 3 bullish, 5 bearish.
  • MRNA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MRNA is a better buy in the short-term than FULC.

Price Growth

FULC (@Biotechnology) experienced а +2.09% price change this week, while MRNA (@Biotechnology) price change was +9.25% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.58%. For the same industry, the average monthly price growth was +17.35%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

FULC is expected to report earnings on Nov 12, 2025.

MRNA is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+7.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRNA($13.2B) has a higher market cap than FULC($422M). FULC YTD gains are higher at: 66.170 vs. MRNA (-17.869). FULC has higher annual earnings (EBITDA): -8.94M vs. MRNA (-3.2B). MRNA has more cash in the bank: 5.98B vs. FULC (227M). FULC has less debt than MRNA: FULC (8.11M) vs MRNA (745M). MRNA has higher revenues than FULC: MRNA (3.14B) vs FULC (80M).
FULCMRNAFULC / MRNA
Capitalization422M13.2B3%
EBITDA-8.94M-3.2B0%
Gain YTD66.170-17.869-370%
P/E RatioN/AN/A-
Revenue80M3.14B3%
Total Cash227M5.98B4%
Total Debt8.11M745M1%
FUNDAMENTALS RATINGS
FULC vs MRNA: Fundamental Ratings
FULC
MRNA
OUTLOOK RATING
1..100
5819
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8996
PRICE GROWTH RATING
1..100
3651
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
16n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (26) in the null industry is somewhat better than the same rating for MRNA (60) in the Biotechnology industry. This means that FULC’s stock grew somewhat faster than MRNA’s over the last 12 months.

FULC's Profit vs Risk Rating (100) in the null industry is in the same range as MRNA (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to MRNA’s over the last 12 months.

FULC's SMR Rating (89) in the null industry is in the same range as MRNA (96) in the Biotechnology industry. This means that FULC’s stock grew similarly to MRNA’s over the last 12 months.

FULC's Price Growth Rating (36) in the null industry is in the same range as MRNA (51) in the Biotechnology industry. This means that FULC’s stock grew similarly to MRNA’s over the last 12 months.

MRNA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for FULC (100) in the null industry. This means that MRNA’s stock grew significantly faster than FULC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCMRNA
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
77%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 10 days ago
88%
Bullish Trend 4 days ago
77%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 6 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KTGDF0.26N/A
+1.37%
K2 Gold Corp
AMIGY45.450.25
+0.55%
Admiral Group Plc.
RUSMF32.85N/A
N/A
Russel Metals Inc.
RHHVF330.52-3.43
-1.03%
Roche Holding Ltd
QTRHF0.95-0.02
-1.66%
Quarterhill Inc.

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with SLS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
-0.13%
SLS - FULC
48%
Loosely correlated
-1.64%
ANNX - FULC
40%
Loosely correlated
-1.57%
VRDN - FULC
39%
Loosely correlated
-1.20%
MRNA - FULC
36%
Loosely correlated
+0.41%
MLTX - FULC
34%
Loosely correlated
+0.07%
More